The sensitivity and specificity of 3 rapid HIV antibody tests were assessed at 5 clinical trial sites in Africa and 1 site in the United States using a minimum of 100 HIV antibody positive samples and 100 HIV antibody negative samples at each site. The overall sensitivity and specificity for the OraSure OraQuick, Abbott Determine, and Trinity Unigold tests were 99.3%, 99.8%, and 98.5%, respectively, and 99.3%, 99.4%, and 99.5%, respectively. There were no instances at any site in which false-negative or false-positive results were obtained for the same sample on more than 1 rapid test kit. The results of this study provide assurance that for these diverse sites in Africa, the accuracy of these kits is quite good. Given the excellent accuracy, relatively fast turnaround time, and minimal infrastructure required, these rapid tests for HIV antibody provide a very attractive and accurate testing format.
Introduction
Several rapid HIV antibody tests using immunochromatographic technology have become available in the last decade. These tests have greatly enhanced access to and ease of HIV testing. 1, 2 The availability of the test result usually within 30 minutes has allowed patients and potential study participants to learn their HIV status at the blood draw visit and has consequently increased uptake of testing.
The sensitivity and specificity of rapid HIV antibody tests have been reported as similar to those of HIV enzyme immunoassays (EIAs) antibody tests (ie, more than 99%), 2, 3 and rapid tests have become the standard for testing in Africa typically replacing the use of EIAs in patient care. 4 Rapid HIV antibody testing has also been adopted for screening for HIV infection to determine eligibility in HIV prevention and therapeutic clinical trials.
In the United States, several of these rapid HIV antibody tests have been approved by the US Food and Drug Administration (FDA) and are considered waived tests by the FDA (http:// www.cdc.gov/hiv/topics/testing/rapid/rt-comparison.htm). Nevertheless, it is good clinical laboratory practice to validate these tests before using them in clinical practice or international clinical trials, given the wide diversity of HIV subtypes in Africa compared to the United States. In preparation for a large vaginal microbicide trial for the prevention of sexual transmission of HIV in Africa and the United States, 5 the sensitivity and specificity of rapid HIV antibody tests to be used in the trial were assessed at 5 clinical trial sites in Africa and 1 site in the United States. All blood samples used for the validation studies at each of the sites were obtained at local clinics, so that samples were likely to be representative of the HIV clades in their communities. The testing was done either using samples of known HIV-1 status or by performing the rapid testing and then the FDA-approved EIA and WB testing. Samples were not specifically tested for HIV-2 antibody as the sites were not in West Africa where HIV-2 is more prevalent. Serum was used at 3 of the African sites (2 used frozen serum and 1 used fresh serum). Frozen plasma was used at 1 of the African sites and at the US site. One African site used fresh whole blood. Serum/ plasma was tested after separation from whole blood collected in EDTA by venipuncture. The technologists or nurses performing the testing were trained, evaluated for competency, and masked to the HIV status of the samples. Table 1 shows each site's calculated sensitivity and specificity data for each kit, the pooled data for each kit across sites, and the sensitivity and specificity stated in the package insert for each kit. The overall sensitivities for the OraQuick, Determine, and Unigold were 99.3%, 99.8%, and 98.5%, respectively; the overall specificities were 99.3%, 99.4%, and 99.5%, respectively. The overall results were slightly below the stated ranges in the test kit package inserts, but were within, or just slightly below, the 95% confidence intervals specified in the package inserts. The sensitivity for each of the 3 kits was not less than 97% at any 1 site. Using pooled data, the sensitivity was not less than 98.5% for any 1 kit. The specificity for each of the . CI, confident interval 3 kits was not less than 97.1% at any 1 site. Using pooled data, the specificity was not less than 99.3% for any 1 kit. There were no instances at any site in which false-negative or false-positive results were obtained for the same sample on more than 1 rapid test kit. Consequently, the percentage of false negatives avoided for the OraQuick, Determine, and Unigold kits were 0.7%, 0.2%, and 0.5%, respectively. The percentage of false positives avoided for the OraQuick, Determine, and Unigold kits were 0.7%, 0.6%, and 0.5%, respectively.
Materials and Methodology

Results
Discussion
Overall, the 3 HIV rapid antibody tests assessed had high sensitivity and specificity, similar to or only slightly below those quoted in the package insert for each test kit. All 3 test kits demonstrated good sensitivity and specificity for use in diverse African settings. No kit demonstrated 100% sensitivity and 100% specificity, but all achieved at least 97% sensitivity and 97% specificity at any 1 given site. No site had a sample that gave a false-negative or false-positive result on more than 1 kit so that, had 2 kits been used in testing samples in parallel, there would likely have been a discordant result requiring confirmation. These results emphasize the importance of using 2 different HIV rapid antibody kits to minimize the number of false-positive and false-negative results. The 3 test kits evaluated are not the only HIV rapid antibody tests available, for use so our results may not apply to other test kits. In addition, we did not determine the HIV subtypes of the samples, although subtype C has been reported to be the predominant HIV subtype of the 5 sites in Southern Africa. 6 Therefore, it is not known whether the sensitivities and specificities observed would have been different given a different mix of HIV subtypes. Nevertheless, the results of this study provide assurance that for these diverse sites in Africa, the accuracy of the tested kits was quite good. Given the excellent accuracy, relatively fast turnaround time, and minimal infrastructure required, these rapid tests for HIV antibody provide a very attractive and accurate testing format.
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